Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma

NCT02538926 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT02538926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02538926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Withdrawn
Start date
July 1, 2018
Completion date
July 30, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia, b lymphoblastic lymphoma, recurrent adult acute lymphoblastic leukemia, recurrent b lymphoblastic lymphoma, recurrent t lymphoblastic leukemia/lymphoma, refractory b lymphoblastic lymphoma, refractory t lymphoblastic lymphoma, t acute lymphoblastic leukemia, t lymphoblastic lymphoma